Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Karenitecin in Primary Malignant Glioma
NCT00062478Phase 2Completed
- Sponsor
- BioNumerik Pharmaceuticals
- Start
- Oct 2001
- Primary completion
- Aug 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of karenitecin in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) and anaplastic oligodendroglioma (AO), sponsored by BioNumerik Pharmaceuticals. Primary endpoint: Objective Tumor Response Rate. Started Oct 2001; status: completed.
02
Drugs
karenitecin
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)anaplastic oligodendroglioma (AO)
Beyond the preview
Go deeper on NCT00062478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062478.